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Optimal conduit choice in the absence of single-
segment great saphenous vein for below-knee
popliteal bypass
James T. McPhee, MD, Neal R. Barshes, MD, C. Keith Ozaki, MD, Louis L. Nguyen, MD, and
Michael Belkin, MD, Boston, Mass
Background: Single-segment great saphenous vein (SSGSV) remains the conduit of choice for femoral to below-knee
popliteal (F–BK) surgical revascularization. The purpose of this study was to determine the optimal conduit in patients
with inadequate SSGSV.
Methods: This was a retrospective review of a prospectively maintained vascular registry. Patients underwent F–BK bypass
with alternative vein (AV; arm vein, spliced GSV, or composite vein) or prosthetic conduit (PC).
Results: From January 1995 to June 2010, 83 patients had unusable SSGSV for F–BK popliteal reconstruction.
Thirty-three patients had an AV conduit and 50 had PC. The AV group was a lower median age than the PC group (69
vs 75 years). The two groups were otherwise similar in comorbid conditions of diabetes mellitus (57.6% vs 58.0%; P >
.99), smoking (15.2% vs 32.0%; P  .12), and hemodialysis (3% vs 12%; P  .23). The groups were similar in baseline
characteristics such as limb salvage as indication (93.9% vs 86.0%; P  .31), mean runoff score (5.2 vs 4.6; P  .39), and
prior ipsilateral bypass attempts (18.2% vs 18.0%; P> .99). The AV and PC groups were also similar in 30-day mortality
(6.1% vs 4.0%; P> .99) and wound infection rates (6.1% vs 6.0%; P> .99). PC patients were more likely to be discharged
on Coumadin (Bristol-Myers Squibb, Princeton, NJ) than AV patients (62.0% vs 27.3%; P  .002). Seventeen of the 50
PC patients (34%) had a distal anastomotic vein cuff. A log-rank test comparison of 5-year outcomes for the AV and PC
groups found no significant difference in primary patency (55.3%  9.9% vs 51.9%  10.8%; P  .82), assisted primary
patency (68.8% 9.6% vs 54.0% 11.0%; P .45), secondary patency (68.4% 9.6% vs 63.7% 10.4% for PC; P .82),
or limb salvage rates (96.2%  3.8% vs 81.1%  8.1%; P  .19). Multivariable analysis demonstrated no association
between conduit type and loss of patency or limb. The factors most predictive of primary patency loss were limb salvage
as the indication for surgery (hazard ratio [HR], 4.23; 95% confidence interval [CI], 1.65-10.9; P  .003) and current
hemodialysis (HR, 3.51; 95% CI, 1.08-11.4; P .037). The most predictive factor of limb loss was current hemodialysis
(HR, 7.02; 95% CI, 1.13-43.4; P  .036).
Conclusions: For patients with inadequate SSGSV, PCs, with varying degrees of medical and surgical adjuncts, appear
comparable to AV sources in graft patency for below-knee popliteal bypass targets. This observation is tempered by the
small cohort sample size of this single-institutional analysis. Critical limb ischemia as the operative indication and current

















dIpsilateral single-segment great saphenous vein (SSGSV)
remains the optimal conduit for infrainguinal revasculariza-
tion. In its absence, the efficacy and safety of using
single-segment contralateral GSV has been well demon-
strated, provided the donor leg has adequate perfusion.1
However, up to 20% to 45% of patients requiring bypass
to a below-knee target will have unusable or unavailable
GSV in either extremity due to prior coronary or lower
extremity revascularization, venous insufficiency, or prior vein
surgery.1,2
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1008It is additionally well accepted that autogenous conduit
s imperative for infrageniculate and pedal targets for any
eaningful attempt at revascularization, as series, including
rosthetic grafts to infrageniculate targets report dismal
atency rates.3 It remains uncertain what the optimal con-
uit is for below-knee popliteal artery bypass in the absence
f usable SSGSV. Existing data evaluating prosthetic con-
uits (PCs) vs alternative vein (AV) sources (arm vein, small
aphenous vein, composite/spliced vein segments) in the
bsence of usable SSGSV are limited and report mixed
esults.4,5 The purpose of this study was to evaluate the
ptimal conduit for below-knee popliteal artery bypass in
he absence of usable SSGSV.
ETHODS
This study was approved by the Brigham and Women’s
ospital Investigational Review Board. This was a retro-
pective analysis of a prospectively maintained vascular sur-
ery registry from January 1995 through June 2010. The
etails of the data set have been previously described but
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Volume 55, Number 4 McPhee et al 1009formed by all members of the Brigham and Women’s
Hospital Vascular Surgery Division.6,7
All patients undergoing below-knee popliteal revascu-
larization with a conduit other than SSGSV for all indica-
tions, including disabling claudication as well as critical
limb ischemia, were included. Patients that had a tibioper-
oneal trunk distal target were also included because we
consider this a comparable recipient vessel to the below-
knee popliteal artery. Patients with infrageniculate targets,
including tibial and pedal targets, were excluded for the
purposes of this investigation.
Each identified patient was included in the study only
once, as defined by the first qualifying leg, to ensure no
patient or limb crossed over between groups or was ana-
lyzed more than once. The overall cohort was divided into
two groups—AV and PC—for the purposes of comparison.
The AV sources included all autogenous sources of small
saphenous vein (SSV), arm vein (basilic/cephalic), spliced
GSV segments, and composite vein grafts. PCs included
externally supported expanded polytetrafluoroethylene
(ePTFE; W. L. Gore and Associates, Flagstaff, Ariz), Da-
cron, precuffed PTFE (Distaflo; Bard, Tempe, Ariz), and
heparin-bonded PTFE (Propaten; W. L. Gore and Associ-
ates).
In general, patients undergo preoperative vein map-
ping in the vascular laboratory or at the outset of the case in
the operating room. In cases of apparently marginal GSV
segments by duplex evaluation, the GSV was explored. The
saphenous vein was considered unusable if upon explora-
tion it was diminutive (3 mm), sclerotic, or unable to be
appropriately dilated during the instillation of vein preser-
vation solution. For below-knee popliteal bypasses per-
formed with PCs, anastomotic adjuncts, such as distal vein
patch, were selectively used based on surgeon preference.
The AV and PC bypass grafts typically underwent sur-
veillance in the vascular laboratory with duplex ultrasound
imaging at 1, 3, 6, and 12 months postoperatively, and
annually thereafter. Grafts were considered at risk in our
vascular laboratory when segmental velocity demonstrated
more than a threefold increase compared with an adjacent
graft segment. A graft was considered to have failed if
further attempts at salvage were abandoned and no seg-
ment of the graft was used to construct a new bypass.
The outflow runoff score was characterized from the
revised standard reporting recommendations by the Society
for Vascular Surgery based on findings from preoperative or
completion diagnostic angiogram or magnetic resonance
angiography, as interpreted by the first study author.8
Other preoperative factors were evaluated, including age,
sex, diabetes mellitus, current smoking, hypertension, cor-
onary artery disease, recent coronary bypass (6 months),
renal insufficiency, current hemodialysis, congestive heart
failure, and dysrhythmia.
The primary outcome measure was graft patency (pri-
mary, assisted primary, secondary). Secondary outcome
measures included limb salvage and patient survival. Imme-
diate postoperative outcomes were additionally evaluated
and included 30-day mortality and morbidity (myocardial tnfarction, stroke, pneumonia, renal failure, and surgical
ite infection). Patency was defined by standard criteria.8
All statistical analyses were performed using SAS 9.2
oftware (SAS Institute, Cary, NC). Univariate analysis of
ategoric variables was performed by the Fisher exact test.
ontinuous data were evaluated by the Student t-test (two-
ailed) if normally distributed and the Wilcoxon rank-sum
est if not normally distributed. A value of P  .05 was
onsidered significant. Multivariable analysis was per-
ormed by backward elimination Cox proportional hazard
egression using values of P  .05 for inclusion in the final
odel. Hazard ratios (HRs) are presented with 95% confi-
ence intervals (CIs).
Factors included in the patency models were age, sex,
iabetes mellitus, smoking, hypertension, coronary artery
isease, current hemodialysis, prior ipsilateral bypass, in-
ow vessel, runoff score, conduit type, indication for pro-
edure, and pertinent discharge medications, including as-
irin, Coumadin (Bristol-Myers Squibb, Princeton, NJ),
nd statins. Only critical limb ischemic patients were in-
luded in the limb salvage model. Survival statistics are
eported by Kaplan-Meier life-table technique. The log-
ank test was used to compare the survival curves.
ESULTS
During the study period, 332 patients underwent fem-
ral to below-knee popliteal bypass (F–BK) at our institu-
ion; 83 (25.0%) were done with AV or PC and comprised
he sample of interest for this study. Of the study cohort, 33
atients (39.8%) had an AV conduit, comprising 27 com-
osite veins (81.2%) and six arm veins (18.2%), and 50
atients (60.2%) had PC, comprising 34 ePTFE (68.0%),
2 heparin-bonded PTFE (24.0%), four Dacron (8.0%),
nd three flared PTFE (6.0%). Of the prosthetic group, 17
atients (34.0%) had a distal anastomotic vein patch (eight
aylor, nine Linton). No patient received a distal arterio-
enous fistula.
Baseline characteristics and unadjusted comparisons of
he AV and PC groups are reported in Table I. The PC
roupwas slightly older than the AV group, withmean ages
f 72.1 and 68 years, respectively (P .042). Limb salvage
as the most common indication for both groups (AV:
3.9% vs PC: 86.0%, P .47). The AV and PC groups were
imilar in sex, ethnicity, and the prevalence of certain pre-
perative comorbid medical conditions such as diabetes
ellitus, current smoking, and hemodialysis-dependent re-
al failure (P  .05 for all). Similar rates of prior ipsilateral
ypass were seen in the AV (18.2%) and PC (18.0%) groups
P  1). Mean runoff score was 5.2 for the AV group and
.6 for the PC group (P .39). Preoperative use of statins,
-blockers, and aspirin was similar for both groups (P .05
or all). Characteristics of the PCs and the surgical and
harmacologic adjuncts are reported in Table II.
Postoperatively, the two groups had similar rates of
0-day major morbidity, including myocardial infarction,
ongestive heart failure, pneumonia, renal failure, and sur-
ical site infection (P  .05 for all; Table III). Postopera-
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April 20121010 McPhee et aldied 30 days (P  .99). The rate of postoperative statin
usage was similar for the AV and PC groups (51.5% vs
64.0%, P .36). Although postoperative aspirin usage was
similar for the AV and PC groups (78.8% vs 69.2%; P 
.45), a higher proportion of PC patients were discharged
on Coumadin (62.0% vs 27.3%; P  .002).
Overall, of the 33 AV patients, nine grafts (27.3%)
ultimately failed. Of those, seven patients had new bypass
grafts created, while two other patients were managed
expectantly for lack of compelling symptoms. Ultimately,
Table I. Baseline characteristics of alternative vein (AV)
and prosthetic conduit (PC) groups for femoral to below-
knee popliteal bypass
Variablea AV (n  33) PC (n  50) P
Age, years
Mean  SD 68  9.8 72.3  10.6 .042
Median (range) 69 (50-86) 75 (42-88)
Female sex 54.6 46.0 .50
White race 81.8 86.0 .45
Comorbidities
Chronic renal failure 9.1 18.0 .35
Hemodialysis 3.0 12.0 .23
Current smoker 15.2 32.0 .12
Diabetes mellitus 57.6 58.0 .99
CAD 57.6 67.3 .49
Hypertension 69.7 72.0 .99
Prior coronary bypass 45.5 42.0 .54
Pre-op medications
Statin 45.4 60.0 .26
-blocker 54.5 66.0 .36
Aspirin only 45.4 36.0 .34
Indication
Limb salvage 93.9 86.0 .31
Prior ipsilateral bypass 18.2 18.0 .99
Runoff score
Mean  SD 5.2  2.3 4.6  2.2 .39
Median (range) 6.0 (1-9.5) 5.0 (1-8.5)
Inflow vessel
Common femoral artery 87.9 90.0 .99
CAD, Coronary artery disease; SD, standard deviation.
aContinuous data are presented as indicated, categoric data are presented as
percentage.
Table II. Prosthetic conduit (PC) types and adjuncts
Variable










Coumadin 21 (61.8) 6 (50.0) 4 (100.0) .22
Clopidogrel 6 (17.6) 2 (16.7) 0 (0) .86





13 (38.2) 1 (8.3) 3 (75.0) .031
PTFE, Polytetrafluoroethylene.two patients (6.1%) in the AV group underwent major wmputation. Of the 50 PC grafts, 11 (22.0%) ultimately
ailed. After failure, new bypass grafts were created in four
atients, and three were managed expectantly. Ultimately,
ve patients (10.0%) in the PC group underwent major
mputation. No statistical difference was noted in the am-
utation rate by conduit type (P  .7).
Five-year patency rates are displayed in the Fig, A-C.
rimary patency was similar at 55.3%  9.9% for AV and
1.9%  10.8% for PC (P  .82). The primary-assisted
atency was 68.8%  9.6% for AV patients and 54.0% 
1.0% for PC patients (P  .45). Secondary patency rates
ere 68.4% 9.6% for AV and 63.7% 10.4% for PC (P
82). At 5 years, AV conduits trended toward improved
imb salvage compared with PC (96.2% 3.8% vs 81.1%
.1%; P .19; Fig,D). Five-year survival was similarly poor
or the AV (57.0% 9.6%) and PC (46.8% 9.3%) groups
P  .27). Five-year primary patency rates were similar
or PC bypass patients discharged with (81.8%  10.2%)
nd without (85.0%  10.2%) Coumadin postopera-
ively (P  .97).
A backward elimination Cox proportional hazard
odel was performed to determine if conduit type pre-
icted loss of patency with adjustment for other factors.
fter adjusted analysis, conduit type was not significantly
ssociated with lost primary (HR, 0.75; 95% CI, 0.33-
.69), assisted primary (HR, 1.13; 95% CI, 0.45-2.83),
econdary patency (HR, 1.07; 95% CI, 0.43-2.66), or limb
oss (HR, 2.16; 95% CI, 0.345-13.6). Factors significantly
redictive of lost patency and limb loss by multivariable
nalysis are reported in Table IV.
ISCUSSION
In this retrospective single-institution cohort study, we
bserved that in the absence of usable SSGSV in the setting
f F–BK popliteal bypass, AV and PC had comparable
rimary, assisted primary, and secondary patency rates at 5
ears. Both groups had similarly acceptable limb salvage
ates and poor 5-year survival rates. For failed grafts, PC
able III. Postoperative data and outcomes for






ischarged on 33 (39.8) 50 (60.2)
Coumadin 9 (27.3) 31 (62.0) .002
Aspirin 26 (78.8) 34 (68.0) .32
Statin 17 (51.5) 32 (64.0) .36
30-day mortality 2 (6.1) 2 (4.0) .99
ajor amputation 2 (6.1) 5 (10.0) .70
ongestive heart failure 1 (3.0) 1 (2.0) .99
yocardial infarction 1 (3.0) 1 (2.0) .99
ound infection 2 (6.1) 3 (6.0) .99
ematoma 0 2 (4.0) .51
erebrovascular
accident
0 1 (2.0) .99
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Volume 55, Number 4 McPhee et al 1011than was AV. The 30-day outcomes, including mortality,
major morbidity, and surgical site infection rates, were
similarly low for both groups.
To our knowledge, this is the first report to evaluate AV
sources vs PCs in a cohort exclusively undergoing bypass to
the below-knee popliteal artery or tibioperoneal trunk.
Although this is a relatively common clinical scenario, there
is a notable lack of literature evaluating this subpopulation
Fig. A, Kaplan-Meier curve demonstrates 5-year prim
(PC) conduits for femoral to below-knee (F–BK) p
error 10%. B, Kaplan-Meier curve demonstrates 5-ye
popliteal bypasses for all indications. *Indicates standar
secondary patency rates for AVs and PCs for F–BK po
demonstrates 5-year limb salvage rates for AVs and
excluded.of dysvascular patients. In contrast, a substantial body of viterature conclusively supports use of SSGSV for lower
xtremity arterial reconstruction, including works from our
wn institution.9-13 The long-term patency superiority of
SGSV over other conduits has been demonstrated at every
istal target level.14 Although the relative merits of using
ein vs PCs for above-knee popliteal targets may be de-
ated,15 little controversy exists regarding the superiority
f SSGSV to below-knee targets, including crural and pedal
atency rates for alternative vein (AV) and prosthetic
eal bypasses for all indications. *Indicates standard
isted primary patency rates for AVs and PCs for F–BK
or10%. C, Kaplan-Meier curve demonstrates 5-year
l bypasses for all indications. D, Kaplan-Meier curve
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April 20121012 McPhee et alundergoing lower extremity revascularization will have ab-
sent or unusable ipsilateral SSGSV.2 Chew et al1 demon-
strated a relative benefit in primary patency of using con-
tralateral SSGSV over AV sources, including arm vein and
spliced GSV, in the absence of usable ipsilateral SSGSV for
infrainguinal reconstructions. They concluded that an ac-
ceptably low rate of contralateral limb intervention and
limb loss is observed in the setting of adequate baseline
perfusion of the donor leg. This observation was not influ-
enced by the presence of diabetes mellitus.
Likewise, little controversy exists regarding the superi-
ority of autogenous conduit to more distal crural and pedal
targets when compared with prosthetic grafts. Reports of
PCs to infrapopliteal targets persistently report dismal pri-
mary patency rates.3 In 1997, Calligaro et al5 reported their
single-center experience comparing arm vein and PCs for
limb salvage to 96 infrapopliteal targets. They noted supe-
rior assisted primary patency and limb salvage rates for AV
compared with prosthetic sources while acknowledging
their overall patency rates were lower than expected based
on other reports.
The data surrounding the clinical question considered
in this report: what is the optimal conduit for below-knee
popliteal arterial bypass in the absence of usable SSGSV, are
less robust and report mixed results. A recent retrospective
report by Arvela et al4 identified 290 patients undergoing
infrainguinal revascularization with arm vein (n  130) or
prosthetic grafts (n 160). Their cohort was inclusive of all
lower extremity targets, making the results not directly
comparable to ours. Not surprisingly, they noted signifi-
cantly improved primary, assisted primary, and secondary
patency rates for AV compared with PC to infrapopliteal
targets (P .05 for all). Similar to our work, they detected
equivalent rates of patency and limb salvage for AV (n 
27) and PC (n  118) to popliteal targets (P  .05 for all
Table IV. Cox proportional hazards for patency and
limb lossa
Variable HR (95% CI) P
Lost primary patency
Conduit type 0.75 (0.33-1.69) .49
Limb salvage indication 4.23 (1.65-10.9) .003
Current hemodialysis 3.51 (1.08-11.4) .037
Lost assisted primary patency
Conduit type 1.13 (0.45-2.83) .79
Limb salvage indication 5.86 (2.17-15.9) .0005
Current hemodialysis 3.57 (1.06-12.0) .04
Lost secondary patency
Conduit type 1.07 (0.43-2.66) .89
Limb salvage undication 7.43 (2.76-20.0) .0001
Limb loss
Conduit type 2.16 (0.345-13.6) .41
Current hemodialysis 7.02 (1.13-43.4) .036
CI, Confidence interval; HR, hazard ratio.
aBackward elimination model included age, sex, diabetes, smoking, hyper-
tension, coronary artery disease, dialysis, prior ipsilateral bypass, inflow
vessel, runoff score, conduit type, indication, and discharge medications.measures). uDirect comparison between the two works is not pos-
ible because they reported above-knee and below-knee
opliteal patency rates in aggregate without specific infor-
ation about the below-knee popliteal arm vein (n  20)
nd prosthetic (n  49) groups. Likewise, they did not
eport rates of postoperative Coumadin usage beyond that
t was not given routinely. Nonetheless, their 3-year pri-
ary (43%), assisted primary (63%), and secondary (63%)
atency rates for 27 AVs were similar to our 5-year rates for
he same measures. Their 3-year patency rates for an aggre-
ate cohort of above-knee and below-knee popliteal pros-
hetic grafts were notably lower than our 5-year isolated
elow-knee popliteal targets with prosthetic grafts for the
ame measures. Our prosthetic graft patency rates for be-
ow-knee popliteal bypass are more in alignment with other
xisting reports.18,19
AV conduits are well-established as an efficacious
eans of lower extremity revascularization to distal arterial
argets.20,21 An older review by Gentile et al22 evaluated
heir results of AV vs SSGSV for critical limb ischemia.
lthough they did not distinguish between above-knee and
elow-knee popliteal artery targets, they reported a 5-year
ssisted primary patency rate of 63% for AV femoropopli-
eal bypasses, which is nearly equivalent to our AV assisted
rimary patency rate of 68% for purely below-knee popliteal
argets at 5 years. The actual expected rate of prosthetic
raft patency to below-knee targets is less clearly defined.
xisting reports differ in the rate of usage of distal anasto-
otic adjuncts, arteriovenous fistulas, graft type, and post-
perative Coumadin usage, making comparative analysis
ifficult. Daenens et al,18 in a recent retrospective analysis,
emonstrated that heparin-bonded ePTFE had similar
-year patency and limb salvage rates compared with au-
ogenous saphenous vein (70% for all); however, no AV
ources were included for comparison. Likewise, they did
ot report rates of postoperative Coumadin usage but did
omment that it was routine after redo venous bypasses.18
A recent industry-supported descriptive report by
osel-Sadee et al23 evaluated a retrospective cohort of
atients undergoing revascularization with heparin-bonded
TFE (Propaten; W. L. Gore and Associates).23 They
bserved exceedingly high 5-year primary and secondary
atency rates for below-knee popliteal targets (70% for
oth) and for crural targets (50% for both). Although
ctual postoperative Coumadin rates were not reported, it
as given routinely for 1 year, if possible. Unfortunately,
hey did not perform a contemporaneous comparison with
enous conduits in their work to allow for more generaliz-
ble comparison.
Factors that may have influenced the observed compa-
able patency rates for the PC group and the AV groupwere
he liberal use of postoperative Coumadin in 60% of the
C patients and that30% of the prosthetic patients had an
djunctive distal anastomotic vein patch. Although these ad-
unctswere not predictive of improvedpatency in this adjusted
nalysis, they have been shown to be beneficial in other
tudies.24 In fact, although causality cannot be proved, the
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cation in this analysis.
In this study, we found that a significantly higher
proportion of patients with PCs were discharged on warfa-
rin therapy. Warfarin therapy at time of hospital discharge
was not found to be protective against graft patency loss by
univariate or adjusted analysis. Authors of other series
evaluating the effect of warfarin therapy on prosthetic graft
patency found it was a significant predictor of graft patency
and limb salvage,25 whereas other series have not.26
The results of this study must be interpreted within the
context of its retrospective study design and limited sample
size. The single-institutional nature of this study limited the
cohort sample size to 83 patients. This limitation leads to
underpowered outcome analyses, leading to the possibility
of type II error or erroneously failing to reject the null
hypothesis that the two conduit types are equivalent in
patency. Although we had an inadequate number of pa-
tients to adjust for confounding by indication by advanced
techniques such as propensity score matching, we did per-
form amultivariable regression to determine if conduit type
predicted patency loss using the Cox proportional hazard
model. Efforts were made to include as many known pa-
tency-related factors as possible, including runoff score, for
both conduit groups in the regression analysis; however, in
the absence of randomized data, we are unable to control
for unmeasured confounders that likely influence patency
rates. Despite this adjustment, no significant association
between conduit type and patency rates was observed. The
finding that hemodialysis is predictive of limb loss is in
alignment with prior observations.27
In summary, in this single-institution retrospective co-
hort study, within the limitations of a small cohort sample
size, no significant difference was observed in patency, limb
salvage, or survival rates among patients undergoing below-
knee popliteal artery bypass with AV sources compared
with PCs in the absence of SSGSV. Critical limb ischemia as
the operative indication is predictive of impaired patency,
and hemodialysis predicts loss of patency and limb loss.
CONCLUSIONS
There is a paucity of high-quality data available in the
current body of literature to make conclusive determina-
tions for this relatively common clinical problem, that
being how best to approach below-knee popliteal artery
revascularization in the absence of usable SSGSV. The
current work found, within the limitations of a small cohort
sample size, comparable outcomes for AV and PC for
below-knee popliteal bypass targets. A larger patient sample
maymore conclusively answer this question in a prospective
randomized trial.
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